FDA Accepts BLA for Afami-Cel for Priority Review as Treatment of Advanced Synovial Sarcoma
Afami-cel had engineered t-cell receptor T-cells target MAGE-A4+ tumors, which are highly expressed in synovial sarcoma with HLA-A*02.
Source: pharmacytimes.com